GlassScriptPhysician profile
Laura A Mcelroy
NPI 1043210537
$9,085.83
in general payments reported to CMS, 2019-2025
28 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,176 · 2022: $1,562 · 2023: $2,299 · 2024: $2,123 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,319 · Consulting Fee: $28.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,319.32 |
| Consulting Fee | $28.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,038.21 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,231.84 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,159.12 | 2021-2025 | Dupixent |
| Csl Behring | $1,079.11 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $1,051.11 | 2021-2025 | |
| Optinose US, INC. | $330.22 | 2021-2025 | |
| Amgen INC. | $304.52 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $283.43 | 2022-2025 | Cuvitru, Takhzyro |
| Teva Pharmaceuticals USA, INC. | $282.13 | 2021-2022 | |
| Kaleo, INC. | $206.01 | 2021-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $138.22 | 2021-2025 | |
| Genentech USA, INC. | $130.27 | 2022-2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $129.80 | 2025 | Neffy |
| Grifols USA, LLC | $100.34 | 2022-2024 | Prolastin-C Liquid, Xembify |
| Blueprint Medicines Corporation | $77.44 | 2024-2025 | Ayvakit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $73.04 | 2024-2025 | Ruconest |
| Pfizer INC. | $70.05 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $69.69 | 2023-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.75 | 2021-2022 | |
| Alk-Abello, INC | $48.71 | 2021-2023 | Grastek, Odactra, Ragwitek |
| Incyte Corporation | $39.80 | 2022-2023 | Opzelura |
| Octapharma USA, INC. | $38.85 | 2022-2024 | Panzyga |
| Mylan Specialty L.P. | $35.89 | 2022-2023 | Yupelri |
| Adma Biomanufacturing LLC | $28.29 | 2025 | |
| Leo Pharma INC. | $25.69 | 2022 | |
| Hikma Pharmaceuticals USA | $21.29 | 2024 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $20.49 | 2025 | |
| Bio Products Laboratory USA, INC. | $19.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.